Gene Therapy For Lethal Glycogen Storage Disease Wins EMA PRIME Designation
Ten products have been granted PRIME designation so far this year
Investigational products from Ultragenyx and MinervaX secured a place on the European Medicines Agency’s priority medicines scheme this month.
